Through its drug discovery and behavioural pharmacology platforms, Affectis has built a pipeline comprising of clinical, preclinical, and discovery candidates in the field of psychiatry and inflammation
| Program | Indication | Discovery | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
| Cimicoxib | Depression | |||||
| AFC-5128 | Neuropathic Pain | |||||
| AFC-08 mAb | Depression | |||||
| Additional Targets | Depression |
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.